Shukra Pharmaceuticals Ltd

1. Standalone Audited Financial Results of the Company for the Quarter and Financial Year ended March 31 2023 along with Statement of Profit & Loss Statement of Assets & Liabilities and the Statement of Cash Flow for the financial year ended March 31 2023 in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations along with the Auditors Reports thereon2. Recommendation of final dividend of 5% (Rs. 0.50 per equity share of Rs. 10 each face value) for the Financial Year 2022-23 subject to the approval of shareholders in the ensuing Annual General Meeting.3. Reviewed the business of the company